TPTakeda PharmaceuticalView brand email archive

Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies

Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies email from Takeda Pharmaceutical screenshot
Screenshot preview · Scroll to view the full email

Archived for design inspiration. Original email and brand assets belong to their respective owners. Design observations describe the creative; they are not campaign results.